Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trial
Key Points
Olaparib combined with irinotecan exhibited significant activity against pediatric tumors.
The strongest effects were seen in tumors with aneuploidy, indicating potential biomarkers for treatment.
Observational analysis across various pediatric malignancies indicated positive responses to this combination therapy.
This research highlights the necessity for further trials to validate findings in larger, more diverse populations.
Abstract
Olaparib combined with irinotecan demonstrated activity in pediatric tumors which was enriched among tumors that exhibited aneuploidy.
AI से पूछें
Like
Bookmark
Share
AI से पूछें
Like
Bookmark
Share
Phase I/II study of the PARP inhibitor olaparib and irinotecan in children and young adults with recurrent/refractory malignancies: Arm D of the AcSé-ESMART trial | Synapse